Monoclonal Antibodies for the Treatment of Hemophilia
Customize your policy alerts
Sign up for univerahealthcare Policy PHARMACY-94 alerts
Get alerted when Policy PHARMACY-94 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage, clinical criteria, and prior authorization requirements for monoclonal antibody therapies used as routine prophylaxis in individuals with hemophilia A or B who have moderate-to-severe disease or a high-risk bleeding phenotype.
No material clinical or coverage changes in this revision.
Coverage and Clinical Eligibility
Initial coverage criteria
Covered when ALL of the following are met
Initial and Recertification Coverage Criteria
Covered when ALL of the following are met
Prior treatment with a gene therapy product for hemophilia is an exclusion to coverage. The policy states that a patient "must not have received previous treatment with a gene therapy product for hemophilia, due to insufficient evidence on safety and/or efficacy of subsequent use with non-factor agents." Requests for monoclonal antibody therapies following prior gene therapy will not be authorized under this policy.
This policy does not apply to Medicare Part D or D‑SNP pharmacy benefits; coverage may apply to other lines of business including Medicare Advantage where appropriate. Additionally, under Medicaid requirements, products manufactured by companies not participating in the Medicaid Drug Rebate Program will not be covered under Medicaid Managed Care/HARP — manufacturers who do not participate render their products ineligible for Medicaid coverage.
Routine use of these non‑factor therapies solely to reduce treatment burden or for patient convenience is not medically necessary. The policy requires documented clinical ineffectiveness of factor replacement therapy (per the criteria) before transitioning to non‑factor monoclonal antibody therapies; use for convenience without evidence of inadequate bleed control will not be authorized.
Codes and billed uses for the therapies addressed in this policy may be designated NMN (not medically necessary) or E/I (experimental/investigational) per the policy code key. Eligibility for reimbursement ultimately depends on the member's contract and the service context (e.g., pharmacy vs medical benefit) and may vary by line of business.
Coding and Product Mapping
Prior Authorization, Documentation, and Step Therapy
Prior authorization required — hematologist prescriber and prophylaxis intent
Prior authorization is required. The medication must be prescribed by, or in consultation with, a hematologist, and must be used for routine prophylaxis to prevent or reduce bleeding frequency.
- Prescriber: prescribed by or in consultation with a hematologist
- Therapy intent: used for routine prophylaxis
Prior authorization and approval time periods vary by line of business
Prior authorization is required for initial and recertification requests. Initial and recertification approval periods vary by line of business — e.g., Commercial/Exchange/Medicare Part B typical initial approval = 6 months; recertification approvals may be 12 months to 2 years depending on line of business.
- Initial approval example: Commercial/Exchange/Medicare Part B = 6 months
- Recertification: 12 months to 2 years (varies by line of business)
Step therapy — Hemlibra trial and failure required for Hemophilia A
Step therapy is required for Hemophilia A: the patient must have had a trial and documented failure of emicizumab (Hemlibra) before coverage of other hemophilia monoclonal antibody therapies will be considered.
- Adequate Hemlibra trial = completion of 4-week loading dose plus ≥24 weeks maintenance with confirmed adherence unless discontinued for serious side effects or neutralizing antibodies
- Failure of Hemlibra defined by increased treated spontaneous/joint bleeds, need for additional factor/bypassing therapy, or failure to prevent target joint bleeds/new joint damage
Recertification may require trial of more cost‑effective alternatives
For recertification, reviewers may require trial of more cost‑effective alternatives as they become available; recertification requires documentation of ongoing benefit and continued medical necessity and may impose step therapy or alternative‑trial requirements per benefit or guideline.
- Recertification must document improvement or stability and continued medical necessity
- Recertification reviews may require trial of generics, biosimilars, or other cost‑effective options when available
Required clinical documentation — hematologist, baseline factor level, and inhibitor testing
Submit documentation showing treating hematologist involvement or consultation; baseline (untreated) factor activity level; and recent inhibitor testing (Hemophilia A: Bethesda assay within 8 weeks; Hemophilia B: Bethesda assay within 6 months unless clinically indicated otherwise).
- Treating hematologist involvement or consultation documented
- Baseline untreated factor activity (FVIII <1% for A or FIX ≤2% for B)
- Recent inhibitor assay: Hemophilia A within 8 weeks; Hemophilia B within 6 months
Required supporting documentation — progress notes, prior treatments, diagnostics
Clinical supporting documentation must be submitted for each request (initial and recertification), including progress notes, prior treatments, diagnostic testing, laboratory results, genetic/biomarker results, imaging, and objective/subjective measures of benefit to demonstrate ongoing medical necessity.
- Progress notes documenting prior treatments and treatment history
- Diagnostic testing and laboratory results (e.g., predose trough levels, inhibitor assays)
- Evidence of clinical benefit (reduction in bleeding, decreased need for intermittent factor/bypassing therapy)
Denial triggers — not meeting prophylaxis criteria or excluded indications
Requests that do not meet the policy's clinical criteria for routine prophylaxis in moderate‑to‑severe hemophilia or a high‑risk bleeding phenotype, or requests for excluded indications (e.g., acquired hemophilia or prior gene therapy), may be denied.
- Failure to meet clinical criteria for routine prophylaxis or high‑risk phenotype is a denial trigger
- Use in acquired hemophilia or after prior gene therapy is excluded and may be denied
Documentation deficiency may result in denial or off‑label review
Requests lacking required clinical documentation (progress notes, treatment history, labs, imaging, or testing) may be denied or subject to off‑label review; absence of objective supporting data for medical necessity can lead to denial or off‑label determination.
- Missing progress notes, prior treatment history, diagnostic testing, lab results, or imaging may cause denial
- Requests may be subject to off‑label review if documentation is insufficient
Medicaid coverage requires Medicaid Drug Rebate Program participation
For Medicaid Managed Care/HARP lines of business, products made by manufacturers that do not participate in the Medicaid Drug Rebate Program (MDRP) will not be covered; manufacturers must participate in the MDRP for Medicaid coverage.
- Medicaid coverage requires manufacturer participation in the Medicaid Drug Rebate Program
- Products from non‑participating manufacturers will not be covered under Medicaid Managed Care/HARP
Clinical Background
Hemophilia A and B are inherited bleeding disorders caused by deficiency of clotting factor VIII (A) or factor IX (B). Disease severity is categorized by baseline untreated factor activity, with severe hemophilia defined as clotting factor level < 1% for FVIII (Hemophilia A) and generally ≤2% for FIX (Hemophilia B). Management centers on factor replacement either episodically or via routine prophylaxis; prophylaxis is the standard of care for individuals with moderate‑to‑severe disease or a high‑risk bleeding phenotype because it reduces bleeding rates and preserves joint function. Patients can develop neutralizing antibodies (inhibitors) to factor products, which complicate replacement therapy and are specifically addressed in the policy's criteria for use of non‑factor monoclonal antibody therapies.
Key Definitions and Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.